Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)
Psilocybin (active compound of "magic mushrooms") is a prototypical psychedelic substance that acts via agonism on serotonin (5-HT) 2A receptors. Psilocybin is rapidly metabolized into its active metabolite psilocin. Psilocybin is currently under investigation as potential treatment for various neuropsychiatric disorders. Psilocybin is also widely used for recreational purposes and as research tool in neuroscience. Besides its current clinical development, a clear characterization of the dose-response relationship of psilocybin is lacking. With the present study the investigators aim to close this knowledge gap by administering low (5mg) to high (40mg) single doses of psilocybin to healthy participants. Besides its agonism on 5-HT2A receptors, psilocin also binds to other receptors and inhibits serotonin transporters (SERT). To this data only few studies have investigated these effects and never at a high dose.
- Status
- recruiting
- Phase
- Phase 1
- Institution
- University Hospital, Basel, Switzerland
- Start date
- 2025-04-21
- End date
- 2026-08-01
- Registry ID
- NCT06796361
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.